AI Summary
This study focuses on the use of a combination of immune checkpoint inhibitors, Ipilimumab and Nivolumab, in molecularly-selected patients with castration-resistant prostate cancer. The aim is to investigate the efficacy and safety of this treatment approach in a subset of patients who display a more immunogenic profile. The results of this study could provide insights into potential new treatment options for these specific mCRPC patients.
Metastatic castration-resistant prostate cancer (mCRPC) typically exhibits resistance to immune checkpoint inhibitors (ICIs). However, a subset of mCRPC patients displays a more immunogenic profile. This study examines efficacy and safety of dual ICI therapy in molecularly selected mCRPC.